

2nd hall

Selected poster presentations					
PB001	Day 2	7:30-8:40	Quantification of skin denervation in patients with transthyretin amyloid neuropathy	Masuda, Teruaki	Kumamoto, Japan
PB002	Day 2	7:30-8:40	Effects of Cyclodextrin/Dendrimer Conjugate/shRNA Complex as a Novel Multi-target Drug on Amyloidoses	Jono, Hirofumi	Kumamoto, Japan
PB052	Day 2	7:30-8:40	Detection of misfolded forms of TTR in plasma from patients with hereditary ATTR using conformation-specific TTR antibodies	Higaki, Jeffrey N.	South San Francisco, United States
PB054	Day 2	7:30-8:40	Targeted imaging in cardiac amyloidosis: is 18F-florbetapir the future?	Manwani, Richa	London, United Kingdom
PB065	Day 2	7:30-8:40	Daratumumab Activity is Agnostic to Fc gamma Receptor 3A (FcγR3A) 158 Genotype in Patients with Refractory or Relapsed Systemic AL Amyloidosis.	Lee, Lisa X.	Boston, United States
PB066	Day 2	7:30-8:40	Analysis of clinical features of AL amyloidosis in real world: Single institute analysis of Kumamoto University Hospital	Kawano, Yawara	Kumamoto, Japan
PB067	Day 2	7:30-8:40	"Non-Measurable" Free Light Chains in Newly Diagnosed Patients with AL Amyloidosis: Clinical and Prognostic Implications	Gavriatopoulou, Maria	Athens, Greece

3rd floor

PB001	Day 2	13:00-14:00	Quantification of skin denervation in patients with transthyretin amyloid neuropathy	Masuda, Teruaki	Kumamoto, Japan
PB002	Day 2	13:00-14:00	Effects of Cyclodextrin/Dendrimer Conjugate/shRNA Complex as a Novel Multi-target Drug on Amyloidoses	Jono, Hirofumi	Kumamoto, Japan
PB003	Day 2	13:00-14:00	Utility of Cardiac Transplant for Wild Type Transthyretin Amyloidosis	Grogan, Martha	Rochester, United States
PB004	Day 2	13:00-14:00	Quality of life assessment after 6 months of initiating treatment with Tafamidis in patients with Non-Val30Met mutations	Karla Cárdenas	CDMX, Mexico
PB005	Day 2	13:00-14:00	A novel transthyretin mutation V28S (p.V48S) with a double-nucleotide substitution in the same codon	Okada, Masamitsu	Kumamoto, Japan
PB006	Day 2	13:00-14:00	A case report of osteoarthritis associated with hereditary transthyretin amyloidosis ATTRV30M	Anan, Intissar	Umeå, Sweden
PB007	Day 2	13:00-14:00	Cardiac and Peripheral Vasomotor Autonomic Functions in Hereditary ATTR Amyloidosis with non-Val30Met Mutation	Koike, Haruki	Nagoya, Japan
PB008	Day 2	13:00-14:00	Tafamidis or transplantation of the liver: Which should be chosen for hereditary transthyretin amyloidosis?	Yamashita, Taro	Kumamoto, Japan
PB009	Day 2	13:00-14:00	Is liver transplantation effective for non-V30M hereditary transthyretin amyloidosis ?	Yamashita, Taro	Kumamoto, Japan

PB010	Day 2	13:00-14:00	Changes in nerve excitability indices in hereditary transthyretin amyloidosis	Yamashita, Taro	Kumamoto, Japan
PB011	Day 2	13:00-14:00	Transthyretin amyloid-related cerebral angitis after liver transplantation	Yamashita, Taro	Kumamoto, Japan
PB012	Day 2	13:00-14:00	Evolution of Amyloid Fibrils in Hereditary ATTR Amyloidosis: an Ultrastructural Study	Koike, Haruki	Nagoya, Japan
PB013	Day 2	13:00-14:00	Common Clinicopathological Features in Late-onset Hereditary ATTR Amyloidosis (Ala97Gly, Val94Gly, and Val30Met)	Koike, Haruki	Nagoya, Japan
PB014	Day 2	13:00-14:00	Pathological roles of heparan sulfate S-domains in ATTR amyloidosis	Nishitsuji, Kazuchika	Tokushima, Japan
PB015	Day 2	13:00-14:00	ANTIBODY THERAPY FOR ATTR AMYLOIDOSIS	Akimitsu, Hana	Kumamoto, Japan
PB016	Day 2	13:00-14:00	Evaluation of multiple organ amyloid involvement in systemic AL and ATTR amyloidosis using whole body ¹¹ C-PiB-PET imaging	Ezawa, Naoki	Matsumoto, Japan
PB017	Day 2	13:00-14:00	Hereditary ATTR amyloidosis with cardiomyopathy caused by the novel variant transthyretin Y114S	Nakase, Taku	Kumamoto, Japan
PB018	Day 2	13:00-14:00	Treatment of ATTR cardiomyopathy with a TTR specific antisense oligonucleotide, Inotersen	Benson, Merrill	Indianapolis, United States
PB019	Day 2	13:00-14:00	Parasympathetic Denervation of the Heart: An Early Sign of Transition from Asymptomatic to Symptomatic TTR-FAP	Barroso, Fabio	Buenos Aires, Argentina
PB020	Day 2	13:00-14:00	Albumin/Creatinine (uACR) and Protein/Creatinine (uPCR) ratios in spot urine samples can be used to evaluate albuminuria and proteinuria in hereditary transthyretin amyloidosis patients	Silva, Moises D.	Rio de Janeiro, Brazil
PB021	Day 2	13:00-14:00	Two siblings with hereditary transthyretin amyloidosis: a rare TTR variant T49S (p.T69S)	Masataka, Yuji	Kumamoto, Japan
PB022	Day 2	13:00-14:00	Patient profile with ATTR-FAP and Evaluation of the Safety and Efficacy of Tafamidis meglumine in Japan. - Interim Analysis in Post Marketing Surveillance -	Ishii, Tomonori	Tokyo, Japan
PB023	Day 2	13:00-14:00	Development of amyloid breakers for hereditary ATTR amyloidosis	Teranishi, Yuriko	Kumamoto, Japan
PB024	Day 2	13:00-14:00	Hereditary ATTR amyloidosis with a pseudo-homozygous Ala120Ser (p.Ala140Ser) transthyretin mutation due to a primer site polymorphism	Shibata, Yuka	Sapporo, Japan
PB025	Day 2	13:00-14:00	Current Situation of Presymptomatic Genetic Counselling for Familial Amyloid Polyneuropathy in a Non-endemic Area in Japan	Tashiro, Mari	Nankoku, Japan
PB026	Day 2	13:00-14:00	Non Val30Met mutation, septal hypertrophy and delayed heart/mediastinum ratio are useful predictors of poor clinical outcome in hereditary transthyretin amyloidosis patients.	Hirakawa, Kyoko	Kumamoto, Japan
PB027	Day 2	13:00-14:00	Changes in Biomarkers Staging Systems in the first 3 Months after Presentation of TTR cardiac amyloidosis.	Maurer, Mathew	New York, United States
PB028	Day 2	13:00-14:00	A Novel TTR Mutation in a Patient with Primary Pulmonary Nodular AL- and ATTR-Amyloidosis	Reiter, Thomas J	Vienna, Austria

PB029	Day 2	13:00-14:00	Conduction system disease in transthyretin amyloidosis: Results from THAOS	Lin, Grace	Rochester, United States
PB030	Day 2	13:00-14:00	Early diagnostic tools in hereditary amyloidosis related to transthyretin (hATTR) V30M autonomic neuropathy	Falcão de Campos, Catarina	Lisbon, Portugal
PB031	Day 2	13:00-14:00	Prevalence of peripheral neuropathy in patients with V122I ATTR cardiomyopathy	Kaku, Michelle	Boston, United States
PB032	Day 2	13:00-14:00	The effect of amino acid substitution at position 88 on the structure and stability of transthyretin	Mizuguchi, Mineyuki	Toyama, Japan
PB033	Day 2	13:00-14:00	Development of a Genetically Diverse ATTR Patient-Specific Induced Pluripotent Stem Cell Library for In Vitro Testing of Novel Therapeutics	Giadone, Richard	Boston, United States
PB034	Day 2	13:00-14:00	Comparison of clinical features in transient focal neurological episodes between hereditary transthyretin type and A β type cerebral amyloid angiopathy	Nakajima, Makoto	Kumamoto, Japan
PB035	Day 2	13:00-14:00	An Induced Pluripotent Stem Cell-Based Universal Gene Correction Strategy for Treating Transthyretin Amyloidosis	Giadone, Richard	Boston, United States
PB036	Day 2	13:00-14:00	Molecular mechanism of novel TTR secretion inhibitor JS-K: possible involvement of S-NO modification at Cys10 residue that causes TTR destabilization	Imai, Yoshiki	Kumamoto, Japan
PB037	Day 2	13:00-14:00	Virtual and high-throughput screenings identify novel TTR stabilizers for hereditary ATTR amyloidosis	Sasaki, Ryoko	Kumamoto, Japan
PB038	Day 2	13:00-14:00	Comparison of baseline prognostic survival factors in wild-type versus mutant transthyretin cardiac amyloidosis	aus dem Siepen, Fabian	Heidelberg, Germany
PB039	Day 2	13:00-14:00	A novel transgenic mouse model expressing human ATTR Tyr114Cys	Isoguchi, Aito	kumamoto, Japan
PB040	Day 2	13:00-14:00	Serum diacron-reactive oxygen metabolites (d-ROMs) and biological antioxidant potential (BAP) in patients with ATTR-PN	Obayashi, Konen	Kumamoto, Japan
PB041	Day 2	13:00-14:00	Evaluation of myoelectrical activities of descending colon by electrointestinogram in patients with ATTRm amyloidosis	Sonoda, Yui	Kumamoto, Japan
PB042	Day 2	13:00-14:00	Cardiac failure in familial amyloid polyneuropathy; 3 cases in OITA	Jikumaru, Mika	Yufu, Japan
PB043	Day 2	13:00-14:00	Therapeutic Approach for Transthyretin Amyloidosis by Targeted Delivery of siRNA Ternary Complex with Cyclodextrin/dendrimer Conjugate	Hayashi, Yuya	Kumamoto, Japan
PB044	Day 2	13:00-14:00	Amyloidotic breast nodule in hereditary Transthyretin Amyloidosis (hATTR): a case report.	Buades, Juan	Palma, Spain
PB045	Day 2	13:00-14:00	Pathological and biochemical findings of systemic tissue sites in hereditary transthyretin amyloidosis after liver transplantation	Okazaki, Takahiro	Kumamoto, Japan
PB046	Day 2	13:00-14:00	Targeting transthyretin amyloidosis in the eye with a second-generation stabilizer: AT40X01 displays potent TTR stabilization in the human vitreous	Bezerra, Carla F.	Porto, Portugal
PB047	Day 2	13:00-14:00	The demographic and clinical characteristics of the V122I population in Brazil	Berensztejn, Amanda C.	Rio de Janeiro, Brazil

PB048	Day 2	13:00-14:00	CATCH ATTR - CARpal Tunnel ligament amyloid: The Clue for early identification of Hereditary or wild-type systemic ATTR amyloidosis? A singlecenter, prospective study	aus dem Siepen, Fabian	Heidelberg, Germany
PB049	Day 2	13:00-14:00	Downregulated Cathepsin E expression in circulating monocytes from the preclinical Familial Amyloid Polyneuropathy model	Moreira, João P	Porto, Portugal
PB050	Day 2	13:00-14:00	Significant reduction in proteinuria after treatment with Tafamidis.	Ferrer-Nadal, Asuncion	Palma de Mallorca, Spain
PB051	Day 2	13:00-14:00	Small Fiber Neuropathy Assessments In Early Stages Of hATTR Amyloidosis	Gonzalez-Duarte, Alejandra	Mexico, Mexico
PB052	Day 2	13:00-14:00	Detection of misfolded forms of TTR in plasma from patients with hereditary ATTR using conformation-specific TTR antibodies	Higaki, Jeffrey N.	South San Francisco, United States
PB053	Day 2	13:00-14:00	Amyloid fibril composition within ATTR V30M families	Suhr, Ole B	Umeå, Sweden
PB054	Day 2	13:00-14:00	Targeted imaging in cardiac amyloidosis: is 18F-florbetapir the future?	Manwani, Richa	London, United Kingdom
PB055	Day 2	13:00-14:00	What is the Penetrance of TTR-CA? Insights from Nuclear Scintigraphy	Castano, Adam	New York, United States
PB056	Day 2	13:00-14:00	TTR stabilizers are associated with improved survival in ATTR-CA	Castano, Adam	New York, United States
PB057	Day 2	13:00-14:00	Cardiologists Often Obtain Nuclear Scintigraphy in Patients Suspected of Having Cardiac Amyloidosis without an Assessment for Monoclonal Proteins	Castano, Adam	New York, United States
PB058	Day 2	13:00-14:00	Distribution of amyloid deposition and fibrosis in the short-axis whole section of 9 autopsied hearts of cardiac amyloidosis	Kawamura, Shunji	Tokyo, Japan
PB059	Day 2	13:00-14:00	Prevalence of cardiac amyloidosis among elderly patients with conduction disorders.	López Sainz, Ángela	Madrid, Spain
PB060	Day 2	13:00-14:00	The longitudinal strain and cardiac response in cardiac amyloidosis	Kim, Min sun	Seoul, Korea
PB061	Day 2	13:00-14:00	Significance of 99mTc-aprotinin scintigraphy for cardiac amyloidosis imaging	Awaya, Toru	Tokyo, Japan
PB062	Day 2	13:00-14:00	Single or combined cardiac transplantation for Cardiac Amyloidosis A report from the French National Referral Center for Cardiac Amyloidosis.	Guendouz, Soulef	Créteil, France
PB063	Day 2	13:00-14:00	Global longitudinal strain as a prognostic marker for familial amyloid cardiomyopathy (FAC)	Baumgärtner, Christian	Heidelberg, Germany
PB064	Day 2	13:00-14:00	Development of a radioiodinated Thioflavin-T derivative for nuclear imaging of systemic amyloidosis	Hagimori, Masayori	Nagasaki, Japan
PB065	Day 2	13:00-14:00	Daratumumab Activity is Agnostic to Fc gamma Receptor 3A (FcγR3A) 158 Genotype in Patients with Refractory or Relapsed Systemic AL Amyloidosis.	Lee, Lisa X.	Boston, United States
PB066	Day 2	13:00-14:00	Analysis of clinical features of AL amyloidosis in real world: Single institute analysis of Kumamoto University Hospital	Kawano, Yawara	Kumamoto, Japan

PB067	Day 2	13:00-14:00	"Non-Measurable" Free Light Chains in Newly Diagnosed Patients with AL Amyloidosis: Clinical and Prognostic Implications	Gavriatopoulou, Maria	Athens, Greece
PB068	Day 2	13:00-14:00	Clinical potential of dual-energy cardiac CT in cardiac amyloidosis using a dual-layer spectral detector scanner	Oda, Seitaro	Kumamoto, Japan
PB069	Day 2	13:00-14:00	Aggregated Light Chain Increases Brain Natriuretic Peptide Production and Induces Oxidative Stress Response in Cardiomyocytes	Tam, Stephen J.	South San Francisco, United States
PB070	Day 2	13:00-14:00	Validation of new renal response criteria in AL amyloidosis treated with high dose melphalan and stem cell transplantation	Sanchorawala, Vaishali	Boston, United States
PB071	Day 2	13:00-14:00	Free light chains dimerization patterns may predict transition from benign to malignant forms of monoclonal gammopathy	Kukuy, Olga	Ramat Gan, Israel
PB072	Day 2	13:00-14:00	Modulating the cardiotoxic behaviour of immunoglobulin light chain dimers through point mutations	Maritan, Martina	Milano, Italy
PB073	Day 2	13:00-14:00	Prevalence of digestive manifestations in patients with amyloidosis	Aguirre, María Adela	C.A.B.A., Argentina
PB074	Day 2	13:00-14:00	Bortezomib therapy before autologous stem cell transplantation might improve overall survival in patients with immunoglobulin light chain amyloidosis	Aguirre, María Adela	Buenos Aires, Argentina
PB075	Day 2	13:00-14:00	Digoxin use in systemic light chain (AL) amyloidosis: contra-indicated or cautious use?	Muchtar, Eli	Rochester, United States
PB076	Day 2	13:00-14:00	Retrospective analysis of 45 cases with cardiac AL amyloidosis in our hospital.	Fuchida, Shin-ichi	Kyoto, Japan
PB077	Day 2	13:00-14:00	Responses and Outcomes for patients with relapsed refractory AL amyloidosis treated with Pomalidomide	Sharpley, Faye A	London, United Kingdom
PB078	Day 2	13:00-14:00	Mass spectrometry to Measure Response in Immunoglobulin light chain amyloidosis (AL)	Dispenzieri, Angela	Rochester, United States
PB079	Day 2	13:00-14:00	Therapeutic impact of lenalidomide-dexamethasone for patients with relapsed or refractory systemic light chain (AL) amyloidosis	Ueno, Akihiro	Matsumoto, Japan
PB080	Day 2	13:00-14:00	High-dose melphalan and autologous stem-cell transplantation for systemic AL amyloidosis: Updated long-term analysis of 66 cases.	Tsukada, Nobuhiro	Tokyo, Japan
PB081	Day 2	13:00-14:00	AL amyloidosis in Argentina: the Hospital Italiano de Buenos Aires	Nucifora, Elsa Mercedes	C.A.B.A., Argentina
PB082	Day 2	13:00-14:00	Concurrent structural and biophysical traits link with immunoglobulin light chains amyloid propensity	Maritan, Martina	Milano, Italy
PB083	Day 2	13:00-14:00	Prognostic significance of D-dimer in patients with AL amyloidosis	Sarosiek, Shayna	Boston, United States
PB084	Day 2	13:00-14:00	Peritumoral AL Amyloidosis Associated With Mantle Cell Lymphoma with Plasmacytic Differentiation: Study of 3 Cases	Yabe, Mariko	New York, United States
PB085	Day 2	13:00-14:00	Light Chain Glycosylation in Patients with Immunoglobulin light chain amyloidosis (AL)	David Murray	Rochester, United States
PB086	Day 2	13:00-14:00	Detecting monoclonal proteins by MASS-FIX in patients with AL organ progression and complete response (CR) by conventional methods	Hwa, Yi Lisa	Rochester, United States

PB087	Day 2	13:00-14:00	Cardiac amyloidosis – Importance of advanced cardiac imaging and clinical persistence	Laptseva, Natalia	Baden, Switzerland
PB088	Day 2	13:00-14:00	Translocation (11;14) And Survival Of Patients With AL Amyloidosis	Yogo, Takao	Tokyo, Japan
PB089	Day 2	13:00-14:00	Pathological and biochemical features in a case with localized pharyngeal AL/ AH amyloidosis	Torikai, Tessei	Kumamoto, Japan
PB090	Day 2	13:00-14:00	Evaluation of Minimal Residual Disease using Next Generation Flow Cytometry in patients with AL amyloidosis	Kastritis, Efstathios	Athens, Greece
PB091	Day 2	13:00-14:00	AL amyloidosis diagnosed using anti-IGLL5 antibody: a case report	Hiroi, Takayuki	Wakayama, Japan
PB092	Day 2	13:00-14:00	A Diagnostic Challenging Case Manifesting Cranial Polyneuropathy and Cauda Equina Syndrome; a case report of primary light chain amyloidosis	Nakano, Yoshikazu	Chiba, Japan
PB093	Day 2	13:00-14:00	A Case Report – Renal Heavy Chain Amyloidosis and T-cell Large Granular Lymphocytic Leukemia	Fu, Julie	Watertown, United States
PB094	Day 2	13:00-14:00	Lenalidomide, dexamethasone and cyclophosphamide as first-line therapy for patients with immunoglobulin AL amyloidosis not eligible for autologous transplant: long-term follow-up of a phase 2 Pethema/GEM study	Cibeira, M. Teresa	Barcelona, Spain
PB095	Day 2	13:00-14:00	T1 Mapping correlates with treatment response in AL amyloidosis	Cibeira, M. Teresa	Barcelona, Spain
PB096	Day 2	13:00-14:00	Daratumumab-Based Therapies in Patients with AL Amyloidosis	Abeykoon, Jithma	Rochester, United States
PB097	Day 2	13:00-14:00	AA type Amyloidosis and Atypical Familial Mediterranean Fever with E148Q and M680I Mutations	Ito, Mayumi	Nagakute, Japan
PB098	Day 2	13:00-14:00	Human serum amyloid A1 transgenic mouse model	Benson, Merrill	Indianapolis, United States
PB099	Day 2	13:00-14:00	Prevalence of AA amyloidosis in Swedish and Italian cattle: possible implications for transmission to humans	Westermarck, Per	Uppsala, Sweden
PB100	Day 2	13:00-14:00	Up-regulation of serum amyloid A3 mRNA expression after stimulation with lipopolysaccharide and lipoteichoic acid in mouse lung cells	Inoshima, Yasuo	Gifu, Japan
PB101	Day 2	13:00-14:00	Gout as the second cause of AA amyloidosis in New Caledonia	Cazorla, Cecile	Dumbea, France
PB102	Day 2	13:00-14:00	DNA aptamer raised against the C-terminal domain of β 2-microglobulin inhibits the fibrillogenesis of Δ N6 β 2m	Tsuda, Yukimoto	Kumamoto, Japan
PB103	Day 2	13:00-14:00	Nationwide survey on cerebral amyloid angiopathy in Japan	Sakai, Kenji	Kanazawa, Japan
PB104	Day 2	13:00-14:00	New Variant of Beta2 Microglobulin V27M in a Patient With with Dialysis- Related Amyloidosis	Mizuno, Hiroki	Tokyo, Japan
PB105	Day 2	13:00-14:00	Solution surface effects on an amyloid- β peptide studied by molecular dynamics simulations	Itoh, Satoru	Okazaki, Japan
PB106	Day 2	13:00-14:00	Clinical and MRI characteristics and follow-up studies of insulin-derived amyloidosis	Nagase, Terumasa	Ami, Japan

PB107	Day 2	13:00-14:00	Investigation of cerebral microbleeds in Alzheimer's disease	Kuroda, Takeshi	Tokyo, Japan
PB108	Day 2	13:00-14:00	Memantine reduces cerebral amyloid angiopathy and spontaneous cerebral hemorrhages in mouse models of cerebral amyloid angiopathy	Inoue, Yasuteru	Kumamoto, Japan
PB109	Day 2	13:00-14:00	Cortical superficial siderosis: prevalence and diagnostic significance for Alzheimer's disease in a memory clinic setting	Inoue, Yasuteru	Kumamoto, Japan
PB110	Day 2	13:00-14:00	Class I small leucine-rich proteoglycans (SLRPs) colocalize with the A β 2M amyloid deposits: Implications for the roles of SLRP core proteins in the pathogenesis of dialysis-related amyloidosis	Yamaguchi, Itaru	Yoshida, Japan
PB111	Day 2	13:00-14:00	Clinical features of camptocormia in patients with Parkinson's disease	Nakane, Shunya	Kumamoto, Japan
PB112	Day 2	13:00-14:00	Correlation of heart rate variability analysis and MIBG myocardial scintigraphy in patients with PD	Nakahara, Keiichi	Kumamoto, Japan
PB113	Day 2	13:00-14:00	Correlations of cognitive and motor functions with visual and quantitative assessments of 123I-ioflupane SPECT in drug-naïve early Parkinson's Disease	Murakami, Hidetomo	Tokyo, Japan
PB114	Day 2	13:00-14:00	Detection of Amyloidosis in Human Tissues using Mid-Infrared Spectroscopic Imaging.	Picken, Maria M.	Schaumburg, United States
PB115	Day 2	13:00-14:00	Severe retinal microvascular dysfunction: The eye – a window to amyloidosis.	Flammer, Andreas	Zurich, Switzerland
PB116	Day 2	13:00-14:00	Bortezomib maintenance for the treatment of Monoclonal Gammopathy of Renal Significance	Lee, Holly	Calgary, Canada
PB117	Day 2	13:00-14:00	Monoclonal Gammopathy of Renal Significance: Experience from a single institution	Lee, Holly	Calgary, Canada
PB118	Day 2	13:00-14:00	Utility of routine use of an immunochemical panel (ELISA-4-Fat) for typing the four main types of systemic amyloidosis in fat tissue	Hazenberg, Bouke P	Groningen, Netherlands
PB119	Day 2	13:00-14:00	A new type of localized subcutaneous pharmaceutical amyloidosis caused by deposition of peptide drug liraglutide	Dogan, Ahmet	New York, United States
PB120	Day 2	13:00-14:00	Cell type differences in internalization of alpha-synuclein aggregates through cell surface heparan sulfate	Ihse, Elisabet	Uppsala, Sweden
PB121	Day 2	13:00-14:00	Renal transplantation following autologous stem cell transplantation in patients with AL amyloidosis	Jaffer Sathick, Insara	New York, United States